Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction
Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. European Journal Of Heart Failure 2024, 26: 1524-1538. PMID: 38700986, DOI: 10.1002/ejhf.3263.Peer-Reviewed Original ResearchConceptsVisual analogue scaleEjection fractionEQ-5D-5L visual analogue scaleHealth-related quality of lifeIndex scorePatient-level pooled analysisComposite of cardiovascular deathQuality of lifeSafety of dapagliflozinEffects of dapagliflozinReduced ejection fractionAssociated with better outcomesPrevalence of comorbiditiesEuroQol 5-dimension questionnaireMeasures of health-related quality of lifePatient self-reportDAPA-HFWorsening HFVAS scoreClinical characteristicsAtrial fibrillationComposite outcomeHeart failurePooled analysisAnalogue scale